News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Eastman shares pulled back to about $63, presenting a buy-the-dip opportunity for a short-term rebound.
  • Company generates $539M free cash flow, trades at 8.4x EV/EBITDA and yields 5.3%, supporting the dividend.
  • Trade plan targets a rebound to $72 within 45 trading days with a protective stop at $58.
  • Femasys raised $8.0M to fund a European commercial rollout and hire sales staff.
  • Management secured new European approvals and partnerships enabling the planned sales launch.
  • Trade suggestion: entry $1.79, target $3.50, stop $1.35, sized as a high-risk small-cap with 180 trading-day horizon.

Latest Articles

Femasys: Launch Is Funded — Back the Sales Rollout, Not the Hype

Femasys: Launch Is Funded — Back the Sales Rollout, Not the Hype

Femasys (FEMY) is a sub-$20M market cap medical device company with new European approvals, partnerships, and an $8.0M financing behind an expanded commercial push. The setup is straightforward: management has the regulatory and product pieces in place and recently raised capital to hire and deploy sales. The stock is oversold technically and carri…

Apple's AI Advantage: Winning the AI Race Without Building Giant Models

Apple's AI Advantage: Winning the AI Race Without Building Giant Models

Apple is not trying to race to build the largest foundation models. Instead it is embedding smarter AI into devices and services where it already wins: privacy-first on-device features, tighter ecosystem lock-in, and higher-margin services. The balance sheet, cash generation, and services profitability give Apple room to monetize AI on its terms. T…

Innodata: Buy the Setback - 50% Selloff Hides Genuine AI Acceleration

Innodata: Buy the Setback - 50% Selloff Hides Genuine AI Acceleration

Innodata has fallen roughly 50% from its 52-week high but is reporting accelerating AI-driven revenue, strong free cash flow and improving operating metrics. The market has punished the stock’s premium multiple; we view that as an opportunity for a mid-term swing aimed at a re-rating if execution continues and commercial pilots convert to recurring…

Sandisk Pullback Play: Short Ahead of Earnings and Tech Concerns

Sandisk Pullback Play: Short Ahead of Earnings and Tech Concerns

Sandisk (SNDK) has been a standout beneficiary of the AI memory supercycle, but price action and technicals show a fresh top formation. With bearish momentum, an upcoming 10/29/2026 earnings event, and renewed headlines about Chinese competition, we outline a tactical short: entry at $1456, stop at $1700, target $1100, mid-term (45 trading days) vi…

Microsoft: A Practical Hedge Against Nvidia Concentration

Microsoft: A Practical Hedge Against Nvidia Concentration

Buy Microsoft for a mid-term re-rate tied to Azure AI commercialization and enterprise adoption of Copilot; trade plan provided with entry, stop, and targets. The thesis is pragmatic: Microsoft can deliver steady AI-driven top-line improvements and margin leverage separate from raw GPU tailwinds, offering a lower-volatility way to own AI exposure w…

Xerox's Pivot Looks Real: A Speculative Long for a 45-Day Trade

Xerox's Pivot Looks Real: A Speculative Long for a 45-Day Trade

Xerox (XRX) is showing the early pieces of a turnaround: positive free cash flow, an EV/EBITDA in the mid-single digits, and a bounce from multi-month lows. The combination of fundamental cheapness and a technical base supports a speculative long with clearly defined risk controls. This trade idea outlines entry, stop and target for a mid-term (45 …

HCA Healthcare: Operational Muscle and Cash Flow Make a Compelling Buy

HCA Healthcare: Operational Muscle and Cash Flow Make a Compelling Buy

HCA Healthcare (HCA) looks priced for resilience, not disappointment. Strong free cash flow, a sub-10x EV/EBITDA multiple and a still-reasonable P/E support a mid-term long trade despite recent headwinds to payer mix. Enter at current levels with a $520 target and a $430 stop; the trade leans on operational improvements and consistent cash generati…

Backing The Big Dog Into Earnings: ASML Asymmetric Trade Ahead Of Q3

Backing The Big Dog Into Earnings: ASML Asymmetric Trade Ahead Of Q3

ASML remains the dominant supplier of extreme ultraviolet (EUV) lithography and benefits from multi-year visibility into customer capex. With Q3 approaching, we prefer a tactical long that buys the stock into uncertainty while capping downside. This is a conviction trade that leans on order backlog resiliency and services revenue growth.

NovoCure: Undervalued Device Franchise with a Clear Path to Re-rating

NovoCure: Undervalued Device Franchise with a Clear Path to Re-rating

NovoCure (NVCR) trades below peers on headline multiples while still generating recurring device revenue from its Optune platform. With a $1.67B market cap, positive regulatory momentum (Optune Pax approval for pancreatic cancer), and elevated short interest, the risk/reward favors a long trade into the next 180 trading days. Entry $14.25, target $…

Avista: High Yield and Cheap Multiples — Buy on Stability of Financing

Avista: High Yield and Cheap Multiples — Buy on Stability of Financing

Avista (AVA) trades near its 52-week low on the back of negative free cash flow and elevated leverage, yet the utility offers a 5.49% yield, a P/E near 13 and a price-to-book around 1.06. If management stabilizes financing and rate cases largely hold, the stock can re-rate toward prior highs. This trade idea lays out entry, stop and target for a lo…

Vylor: A Food-Scarcity Trade With Optional Growth Upside

Vylor: A Food-Scarcity Trade With Optional Growth Upside

Vylor Inc. (VYLR) provides agricultural and crop production services and is trading near its 52-week high at $74.92 with a market cap near $50.0B. High short activity, a modest PB of 2.01 and a forward-looking narrative tied to food scarcity make this a tactical long idea. Entry, stop and target are specified with a mid-term horizon and clearly def…